Graig Suvannavejh
Stock Analyst at Mizuho
(3.55)
# 898
Out of 5,005 analysts
164
Total ratings
47.97%
Success rate
5.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $50 → $35 | $27.28 | +28.30% | 19 | Sep 25, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $43 → $44 | $27.64 | +59.19% | 2 | Sep 12, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $2 → $4 | $2.53 | +58.10% | 9 | Sep 12, 2025 | |
| KALA KALA BIO | Initiates: Outperform | $30 | $1.54 | +1,848.05% | 1 | Sep 8, 2025 | |
| INSM Insmed | Maintains: Outperform | $130 → $165 | $157.16 | +4.99% | 11 | Aug 13, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $21 → $22 | $23.80 | -7.56% | 10 | Aug 4, 2025 | |
| ALEC Alector | Upgrades: Outperform | $2.5 → $3.5 | $3.32 | +5.42% | 5 | Jul 28, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Outperform | $4 → $5 | $1.83 | +173.22% | 2 | Jul 16, 2025 | |
| ADVM Adverum Biotechnologies | Maintains: Outperform | $16 → $12 | $5.39 | +122.63% | 5 | Jun 26, 2025 | |
| ADAP Adaptimmune Therapeutics | Downgrades: Neutral | $1.5 → $0.5 | $0.15 | +225.73% | 3 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $6.05 | +65.29% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $7.19 | +52.99% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $13.73 | +89.37% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $13.42 | -40.39% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $34.21 | -3.54% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $212 → $216 | $120.30 | +79.55% | 21 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.61 | +372.05% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $14.83 | +398.99% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $5 | $4.14 | +20.77% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $44 → $49 | $68.98 | -28.96% | 6 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $9.40 | +70.21% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $8.23 | +21.51% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $4.83 | -79.30% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $99.02 | -64.65% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $15.06 | -46.88% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $56.97 | +0.05% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $36.71 | -86.38% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $11.39 | +198.51% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $6.11 | +358.27% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $15.65 | +98.08% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $37.46 | +914.42% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $2.06 | +131.14% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $19.92 | +80.72% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $37.62 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $1.47 | +2,417.01% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $139.48 | -8.23% | 1 | Sep 14, 2020 |
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Outperform
Price Target: $50 → $35
Current: $27.28
Upside: +28.30%
IDEAYA Biosciences
Sep 12, 2025
Maintains: Outperform
Price Target: $43 → $44
Current: $27.64
Upside: +59.19%
BioXcel Therapeutics
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $2.53
Upside: +58.10%
KALA BIO
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $1.54
Upside: +1,848.05%
Insmed
Aug 13, 2025
Maintains: Outperform
Price Target: $130 → $165
Current: $157.16
Upside: +4.99%
Apellis Pharmaceuticals
Aug 4, 2025
Maintains: Neutral
Price Target: $21 → $22
Current: $23.80
Upside: -7.56%
Alector
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $3.32
Upside: +5.42%
Neumora Therapeutics
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $1.83
Upside: +173.22%
Adverum Biotechnologies
Jun 26, 2025
Maintains: Outperform
Price Target: $16 → $12
Current: $5.39
Upside: +122.63%
Adaptimmune Therapeutics
Jun 26, 2025
Downgrades: Neutral
Price Target: $1.5 → $0.5
Current: $0.15
Upside: +225.73%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $6.05
Upside: +65.29%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $7.19
Upside: +52.99%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $13.73
Upside: +89.37%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $13.42
Upside: -40.39%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $34.21
Upside: -3.54%
Mar 27, 2025
Maintains: Outperform
Price Target: $212 → $216
Current: $120.30
Upside: +79.55%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.61
Upside: +372.05%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $14.83
Upside: +398.99%
Sep 19, 2024
Downgrades: Neutral
Price Target: $50 → $5
Current: $4.14
Upside: +20.77%
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $68.98
Upside: -28.96%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $9.40
Upside: +70.21%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $8.23
Upside: +21.51%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $4.83
Upside: -79.30%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $99.02
Upside: -64.65%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $15.06
Upside: -46.88%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $56.97
Upside: +0.05%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $36.71
Upside: -86.38%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $11.39
Upside: +198.51%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $6.11
Upside: +358.27%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $15.65
Upside: +98.08%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $37.46
Upside: +914.42%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $2.06
Upside: +131.14%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $19.92
Upside: +80.72%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $37.62
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $1.47
Upside: +2,417.01%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $139.48
Upside: -8.23%